Lack of Association of CYP2E1 and CYP1A1 Polymorphisms with Osteoporosis in Postmenopausal Women

Sadegh Fattahi¹, Gholam Ali Yousefi², Galia Amirbozorgi¹, Maryam Lotfi¹
Ali Naeiji¹, Mohsen Asouri¹, Saeid Kavosian¹, Effat Hayati¹, Ali Asghar Ahmadi¹
Haleh Akhavan-Niaki³*

1- North Research Center, Pasteur Institute of Iran, Amol, Iran.
2- Radiology Department, Valiasr Hospital, Social Security Organization, GhaemShahr, Mazandaran, Iran.
3- Department of Genetics and Anatomy, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.

Submitted 20 Oct 2015; Accepted 16 Nov 2015; Published 24 Dec 2015

Osteoporosis is a metabolic bone disease affecting mostly elderly women. As metabolizing enzymes, the roles of few cytochromes have been studied in osteoporosis development. The aim of this study was to assess for the first time the association of CYP2E1 and CYP1A1 polymorphisms and osteoporosis in postmenopausal women. 112 postmenopausal women presenting osteoporosis and 93 age and sex matched healthy controls originating from north Iran were enrolled in this study. Rs2031920 and rs3813867 at CYP2E1 as well as rs4646421 and rs2198843 at CYP1A1 loci were studied in all subjects using polymerase chain reaction and restriction fragment length polymorphism analysis. Genotype analysis for rs2031920 showed that the CT genotype was present only in osteoporotic patients with a frequency of 4.17%. Similarly GC genotype at rs3813867 locus was present only in osteoporotic patients with a frequency of 3.13%. [G; T] and [C; C] haplotypes for rs3813867-rs2031920 were found with low frequencies only in osteoporotic patients. TT genotype at rs4646421 locus was higher in osteoporotic (8.05%) versus control subjects (3.22%), 14.28% of cases were homozygous for the C allele at rs2198843 locus which is higher than controls (11.84%). The [C; G] haplotype for rs4646421-rs2198843 was predominant in cases (54.47%) and controls (58.6%). GT haplotype was rare in both groups. No significant differences in genotypes or haplotypes frequencies were observed among the osteoporotic and normal subjects. CYP1A1 and CYP2E1 loci are not associated to osteoporosis risk in the studied population.

Keywords: Osteoporosis; CYP1A1; CYP2E1; polymorphism

Osteoporosis is a silent metabolic bone disease characterized by low bone mass and reduction in bone mineral density (BMD) leading to increased susceptibility to fractures (1, 2). Different factors such as environmental, genetic, gender, age, nutrition and hormones are associated with osteoporosis (3-6). Women are more affected than men and according to the World Health Organizati
Lack of Association of CYP2E1 and CYP1A1 Polymorphisms

on, 25% of women and 12% of men become affected during their lives (7). Based on, 13% to 18% of women over 50 years have osteoporosis due to minimal ovarian activity that leads to decrease levels of estrogen in postmenopausal women and risk factor for bone loss. Genetic factors including Vitamin D receptor, Estrogen receptor, calcium-sensing receptor and cytochrome P450 genes have been reported as important players in the pathogenesis of osteoporosis (6, 8-10). Estrogen have essential role in bone turnover and establishing balance between bone formation and resorption. Moreover, metabolic pathways related to estrogen are important determinants of bone mineral density (BMD) in postmenopausal women. (11-14). The cytochrome P450 enzymes are a group of heme-containing enzymes placed in the endoplasmic reticulum of hepatocytes. They are required for the removal of carcinogenic compounds from the body (15). They are also essential in the metabolism of many medications, production of numerous agents such as cholesterol, steroids, vitamin D3 and vitamin K as well as metabolism and biosynthesis of estrogen. There are more than 50 CYP450 enzymes but six of them (CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4) metabolize more than 85 percent of drugs and metabolites (16). Cyp1A1, Cyp19, Cyp17, CYP3A4, CYP1A2 and CYP1B1 have been demonstrated to have a role in osteoporosis development (9, 17, 18). Cytochrome P450 2E1 (CYP2E1), a member of the cytochrome P450 superfamily is important for the metabolic activation of many low-molecular-weight toxicants such as N-nitrosamines, aniline, vinyl chloride, urethane and alcohol that is expressed primarily in the liver (19). It has been reported that CYP2E1 polymorphism is involved in several types of diseases including cancer, hepatitis and tuberculosis (20). Recently, it has been reported that Rsal/PstI polymorphism as well as sex hormones may influence human CYP2E1 gene expression (21). Also, it has been reported that CYP1A1 polymorphism may play an important role in estrogen metabolism (22-24). The aim of this study was to investigate for the first time the association between CYP2E1 and CYP1A1 polymorphisms with osteoporosis in a population of postmenopausal women originating from north Iran.

Materials & Methods

Subjects

This case-control study contained 112 postmenopausal women presenting osteoporosis and 93 age and sex matched healthy controls that were referred to Valiasr Hospital in Ghaemshar, Mazandaran, Iran. All subjects consented to participate to this study and demographic data were collected upon personal interview. Also, the study was approved by the scientific and ethics committees of north research center of Pasteur institute, Amol, Iran.

DNA extraction

Genomic DNA was extracted from whole blood using salting out method. Briefly, 5ml whole blood was digested with proteinase K followed by 6M sodium acetate treatment. The DNA was collected after alcohol precipitation, and then dissolved in 10 mM Tris (pH 8.0) and 0.1 mM EDTA.

Analysis of CYP2E1 gene polymorphisms

Two single-nucleotide polymorphisms of CYP2E1 (rs3813867 and rs2031920) were studied by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. The cycling conditions consisted of an initial denaturation at 94 °C for 5 min followed by 35 cycles, each consisting of denaturation at 94 °C for 45 seconds, annealing at 59°C for 1 min, extension at 72 °C for 60 seconds and one final cycle of extension at 72°C for 7 min. The PCR products were
digested overnight with either RsaI (rs2031920) or PstI (rs3813867) restriction enzymes at 37°C. The evaluation of the digestion patterns was achieved by electrophoresis on a 3% agarose gel followed by ethidium bromide staining. The expected sizes of the products after digestion with RsaI were as follows: 413 bp for the T allele (no cutting), 354 bp and 59 bp for the C allele. The expected sizes after digestion with PstI are 299 bp and 114 bp for the C allele, while the G allele remains uncut with 413 bp size.

**Analysis of CYP1A1 gene polymorphisms**

We developed specific PCR–restriction fragment length polymorphism tests for two single-nucleotide polymorphisms of CYP1A1 (rs4646421 and rs2198843). PCRs for both SNPs were performed under following conditions, after initial denaturation at 95 °C for 5 minutes, 35 cycles each consisting of denaturation at 94 °C for 45 seconds, annealing at 60 °C for 45 seconds, extension at 72 °C for 45 seconds and a final elongation step at 72 °C for 7 minutes were performed. The PCR products were digested overnight with either NspI (rs4646421) or PstI (rs2198843) restriction enzyme at 37°C and the presence of restriction sites was identified by agarose gel electrophoresis. The information about sequence of primer pairs, size of PCR products and digested products with restriction enzymes is listed in Table 1.

**Statistical analyzes**

The χ² test was used to evaluate differences in the distributions of genotypes and allele frequencies between cases and controls. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to describe the strength of associations. An adjusted two-tailed P value less than 0.05 at 95% CI was considered as statistically significant.

**Results**

**Age and BMD analysis**

In this study, we examined 112 postmenopausal cases with osteoporosis aged 59.35± 7.76 years and 93 normal subjects aged 57.37± 5.56 years. The BMD analyzes showed that BMD was significantly lower in osteoporosis patients (0.817± 0.074) than normal subjects (1.231± 0.104) (P< 0.0001).

**CYP2E1 genotyping**

The frequencies of C and T alleles for rs2031920 as well as genotype distribution among studied subjects are shown in Table 2. The C allele was present in all normal subjects while its frequency was 0.982 among osteoporotic subjects. The wild type homozygous genotype (CC) was the most frequent in osteoporotic subjects (96.42%) as well as in normal subjects (100%). None of the analyzed subjects showed TT genotype. RsaI polymorphism genotype distributions were in Hardy-Weinberg equilibrium (P= 0.847). Figure 1A

---

**Table 1. PCR and RFLP conditions for the CYP1A1 and CYP2E1 genotyping**

<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP</th>
<th>Primer sequence</th>
<th>PCR product (bp)</th>
<th>Enzyme</th>
<th>RFLP product (bp)</th>
<th>Reference or source</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A1</td>
<td>rs4646421</td>
<td>F: 5'-GCTCAATCTAGCTGTCTCCA -3' R: 5'-GAGTCTACCACCA CACTTAG-3'</td>
<td>417</td>
<td>NspI</td>
<td>231, 138</td>
<td>This study</td>
</tr>
<tr>
<td>CYP1A1</td>
<td>rs2198843</td>
<td>F: 5'-GTCCCTCAGAGACA AGGCG -3' R: 5'-CTCCTTCAGCTTC ACGGCA-3'</td>
<td>404</td>
<td>PstI</td>
<td>299, 105</td>
<td>This study</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>rs2031920</td>
<td>F: 5'-CCA GTC GAG TCT ACA TTG TCA-3' R: 5'-TTC ATT CTA TCT TCT AAC TGG-3'</td>
<td>413</td>
<td>RsaI</td>
<td>354, 59</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs3813867</td>
<td>F: 5'-CCA GTC GAG TCT ACA TTG TCA-3' R: 5'-TTC ATT CTA TCT TCT AAC TGG-3'</td>
<td>413</td>
<td>PstI</td>
<td>299, 114</td>
<td>(25)</td>
</tr>
</tbody>
</table>
represents the electrophoresis pattern after digestion of PCR products with RsAl.

The distributions of the genotypes and frequencies of C and G alleles for rs3813867 of the studied subjects are summarized in Table 2. The allele frequency for the G allele among osteoporotic population was 0.986, while all control subjects had the G allele. The wild type homozygous genotype (GG) was the most frequent in both groups. None of the analyzed subjects showed CC genotype. PstI polymorphism genotype distributions were in Hardy-Weinberg equilibrium (P= 0.885). Figure 1A is a representative of PstI genotyping analysis on PCR products of CYP2E1 gene.

**Table 2. Distribution of CYP2E1 and CYP1A1 genotype and allele frequencies in osteoporotic cases compared to controls for rs2031920, rs3813867, rs4646421 and rs2198843**

<table>
<thead>
<tr>
<th>rs2031920 polymorphism</th>
<th>C allele</th>
<th>T allele</th>
<th>CC</th>
<th>CT (95%)</th>
<th>TT (95%)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osteoporosis (n=112)</td>
<td>0.982</td>
<td>0.018</td>
<td>108(96.42)</td>
<td>4(3.58)</td>
<td>0</td>
<td>1.00</td>
</tr>
<tr>
<td>Normal (n=93)</td>
<td>1</td>
<td>0</td>
<td>93(100)</td>
<td>0</td>
<td>0</td>
<td>7.75(0.41-145)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>rs3813867 polymorphism</th>
<th>G allele</th>
<th>C allele</th>
<th>GG</th>
<th>GC</th>
<th>CC</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osteoporosis (n=112)</td>
<td>0.986</td>
<td>0.014</td>
<td>109(97.32)</td>
<td>3(2.68)</td>
<td>0</td>
<td>1.00</td>
</tr>
<tr>
<td>Normal (n=93)</td>
<td>1</td>
<td>0</td>
<td>93(100)</td>
<td>0</td>
<td>0</td>
<td>5.9772 (0.30-117)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>rs4646421 polymorphism</th>
<th>C allele</th>
<th>T allele</th>
<th>CC</th>
<th>CT (95%)</th>
<th>TT (95%)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osteoporosis (n=112)</td>
<td>0.767</td>
<td>0.233</td>
<td>69(61.6%)</td>
<td>34(30.35 %)</td>
<td>9(8.05%)</td>
<td>1.1498(0.62-2.11)</td>
</tr>
<tr>
<td>Normal (n=93)</td>
<td>0.822</td>
<td>0.178</td>
<td>63(67.6%)</td>
<td>27(29.09%)</td>
<td>3(3.22%)</td>
<td>2.7391(0.70-10.57)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>rs2198843 polymorphism</th>
<th>G allele</th>
<th>C allele</th>
<th>GG</th>
<th>GC</th>
<th>CC</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osteoporosis (n=112)</td>
<td>0.674</td>
<td>0.326</td>
<td>55(49.10 %)</td>
<td>41(36.62%)</td>
<td>16(14.28 %)</td>
<td>1.1069(0.60-2.01)</td>
</tr>
<tr>
<td>Normal (n=93)</td>
<td>0.704</td>
<td>0.296</td>
<td>49(52.68 %)</td>
<td>33(35.48 %)</td>
<td>11(11.84%)</td>
<td>1.2959(0.54-3.05)</td>
</tr>
</tbody>
</table>

**CYP1A1 genotyping**

The frequencies of the C and T alleles and genotype distribution of rs4646421 are summarized in Table 2. The C and T allele frequencies were found to be 0.822 and 0.178 among the control subjects, and 0.767 and 0.233 among osteoporotic subjects, respectively. The distribution of CC and CT genotypes in osteoporotic cases were 61.6% and 30.35%, respectively compared to 67.6% and 29.09% in healthy controls. TT genotype was higher in osteoporotic subjects (8.05%) versus control subjects (3.22%), but the difference was not significant. Observed genotypes were in Hardy-Weinberg equilibrium (P= 0.1401). Figure 1B sho
The frequencies of the C and G alleles as well as genotype distribution in controls and patients for rs2198843 are shown in Table 2. Allelic frequencies for G and C allele were 0.674 and 0.326 among osteoporotic subjects versus 0.704 and 0.296 in control subjects, respectively. The distribution of GG and GC genotypes in osteoporotic cases was 49.1% and 36.62% compared to 52.68% and 35.48% in healthy controls, respectively. As shown in Table 1, 14.28% of osteoporotic cases were homozygous for the C allele which is higher than controls (11.84%) but the difference is not significant. Genotype distributions of rs2198843 was in Hardy-Weinberg equilibrium (P= 0.1401). The electrophoresis pattern after digestion of PCR products with NspI is shown in figure 1C.

Table 3 Associations between [rs3813867; rs2031920] haplotypes of CYP2E1 and osteoporosis

<table>
<thead>
<tr>
<th>Haplotype</th>
<th>Osteoporosis n (%)</th>
<th>Normal n (%)</th>
<th>OR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>[G; C]</td>
<td>218 (97.32)</td>
<td>186 (100)</td>
<td>1.00 (reference)</td>
<td></td>
</tr>
<tr>
<td>[G; T]</td>
<td>1 (0.446)</td>
<td>0</td>
<td>2.5606(0.10-63.23)</td>
<td>0.56</td>
</tr>
<tr>
<td>[C; C]</td>
<td>1 (0.446)</td>
<td>0</td>
<td>2.5606(0.10-63.23)</td>
<td>0.56</td>
</tr>
</tbody>
</table>

*For 1.8% of the analyzed subjects haplotype assignment was not possible due to heterozygocity in both loci.

Haplotype data for rs2031920 and rs3813867 at CYP2E1 locus are provided in Table 3. Our study revealed that the osteoporotic population has three haplotypes, while healthy controls have only one haplotype. But no significant difference in distribution of the common haplotype was observed in patients with osteoporosis and healthy controls. The predominant haplotype in this study was [G; C] Table 3.

Haplotype data for rs4646421 and rs2198843 at CYP 1A1 locus are shown in Table 4. Four haplotypes were identified in osteoporotic as well as normal subjects. The haplotype [C; G] was predominant in osteoporotic (54.47%) and control subjects (58.6%). In this study, [G; T] haplotype was rare in both osteoporotic and normal subjects.
Many genetic factors were reported as having a significant effect on bone remodeling and bone mass. Therefore, polymorphism in genes controlling drugs and metabolism such as CYP450 may act as strong candidate loci for increased risk of genetically influenced disorders such as osteoporosis. Several studies show that the genetic polymorphisms in CYP450 are associated with osteoporosis in postmenopausal women (9, 17, 18, 26, 27). However, there is no information about the impact of CYP2E1 (RsaI/PstI) genetic polymorphisms on osteoporosis susceptibility. This is the first study evaluating the CYP2E1 polymorphisms in osteoporotic subjects. In this study, rs2031920 and rs3813867 were studied in 93 healthy subjects and 112 patients with osteoporosis. Genotype analysis for rs2031920 showed that the CT genotype was present only in osteoporotic patients with a frequency of 3.58%. Genotype analysis for rs3813867 showed that the GC genotype was present only in osteoporosis patients with a frequency of 2.68%. There were no significant differences in genotype frequencies among the osteoporotic and normal subjects although the risk for the heterozygous genotype was seven-fold greater than the homozygous wild type CC genotype for rs2031920 (OR= 7.75) in osteoporotic cases. Similarly, the risk for the heterozygous genotype was five-fold greater than the homozygous wild type GG genotype for rs3813867 (OR= 5.9772) in osteoporotic cases. Haplotypes distribution at CYP2E1 locus was not significantly different between the osteoporotic subjects and control s (P= 0.5), but the risk for the [G; T] and [C; C] haplotype subjects to have osteoporosis is three-fold greater than it is for the [G; C] haplotype (OR= 2.56). Our findings on alleles and genotype frequencies are similar to another study in Iran which analyzed two hundred healthy individuals from the southwest population (28). The comparison of genotype distribution between Iranian and other populations shows that its distribution is similar to Indian, Turkish and some European populations such as German, British and French (21, 29-32) but is different from other Asians, including Japanese and Chinese and also from Italians (33-35). Based on WHO criteria, 11.9% of Native American women, 10% of Asians, 9.8% of Hispanics, 7.2% of Whites, and 4.2% of Blacks were osteoporotic (36). These distribution differences among ethnicities strongly support the genetic contribution to disease occurrence. Cyp17 and CYP 19 enzymes are involved in estrogen biosynthesis while CYP3A4, CYP1A2, CYP1B1 and CYP1A1 contribute to its metabolism (37). Polymorphism in the cytochrome P450 enzymes related to estrogen biosynthesis and metabolism may lead to increased risk of hormone-dependent disorders such as breast cancer (23, 24, 38-41) and osteoporosis (9, 17, 18, 26). It has been reported that CYP1A1 polymorphism may play an

### Discussion

Many genetic factors were reported as having a significant effect on bone remodeling and bone mass. Therefore, polymorphism in genes controlling drugs and metabolism such as CYP450 may act as strong candidate loci for increased risk of genetically influenced disorders such as osteoporosis. Several studies show that the genetic polymorphisms in CYP450 are associated with osteoporosis in postmenopausal women (9, 17, 18, 26, 27). However, there is no information about the impact of CYP2E1 (RsaI/PstI) genetic polymorphisms on osteoporosis susceptibility. This is the first study evaluating the CYP2E1 polymorphisms in osteoporotic subjects. In this study, rs2031920 and rs3813867 were studied in 93 healthy subjects and 112 patients with osteoporosis. Genotype analysis for rs2031920 showed that the CT genotype was present only in osteoporotic patients with a frequency of 3.58%. Genotype analysis for rs3813867 showed that the GC genotype was present only in osteoporosis patients with a frequency of 2.68%. There were no significant differences in genotype frequencies among the osteoporotic and normal subjects although the risk for the heterozygous genotype was seven-fold greater than the homozygous wild type CC genotype for rs2031920 (OR= 7.75) in osteoporotic cases. Similarly, the risk for the heterozygous genotype was five-fold greater than the homozygous wild type GG genotype for rs3813867 (OR= 5.9772) in osteoporotic cases. Haplotypes distribution at CYP2E1 locus was not significantly different between the osteoporotic subjects and control s (P= 0.5), but the risk for the [G; T] and [C; C] haplotype subjects to have osteoporosis is three-fold greater than it is for the [G; C] haplotype (OR= 2.56). Our findings on alleles and genotype frequencies are similar to another study in Iran which analyzed two hundred healthy individuals from the southwest population (28). The comparison of genotype distribution between Iranian and other populations shows that its distribution is similar to Indian, Turkish and some European populations such as German, British and French (21, 29-32) but is different from other Asians, including Japanese and Chinese and also from Italians (33-35). Based on WHO criteria, 11.9% of Native American women, 10% of Asians, 9.8% of Hispanics, 7.2% of Whites, and 4.2% of Blacks were osteoporotic (36). These distribution differences among ethnicities strongly support the genetic contribution to disease occurrence. Cyp17 and CYP 19 enzymes are involved in estrogen biosynthesis while CYP3A4, CYP1A2, CYP1B1 and CYP1A1 contribute to its metabolism (37). Polymorphism in the cytochrome P450 enzymes related to estrogen biosynthesis and metabolism may lead to increased risk of hormone-dependent disorders such as breast cancer (23, 24, 38-41) and osteoporosis (9, 17, 18, 26). It has been reported that CYP1A1 polymorphism may play an
important role in estrogen metabolism (9, 22, 24, 42). Genotype analysis for rs4646421 showed that the frequency of TT genotype was higher in patients with osteoporosis than in controls. Although no significant associations were observed between osteoprotic and normal subjects, but osteoporosis risk was three times greater in individuals with TT genotype than individuals with CC and CT genotypes. Genotype analysis for rs2198843 showed that the distribution of genotypes was approximately similar in both groups. There were no significant differences in genotype frequencies among the osteoporotic subjects and normal ones. Haplotypes were neither significantly different between them (P= 0.07), but the risk for the mutant [T; C] haplotype subjects to have osteoporosis was two times greater than it was for the wild haplotype [C; G] (OR= 2.05). In this study, we found [G; T] and [C; C] haplotypes for CYP2E1 [rs3813867; rs2031920] and [C; T] haplotypes for CYP1A1 [rs4646421; rs2198843] with low frequencies in osteoporotic patients. However, as osteoporosis is a complex disease and many genetic factors may contribute in the development of this disorder, a single polymorphism may not show a significant association with the disease unless it is strongly associated. Thus, other polymorphisms in candidate genes should be studied in order to find a polymorphism panel for osteoporosis risk evaluation. Correspondingly, it was also recommended to study a larger sample size, as minor alleles with strong impact on disease development may have more chances to be identified. Moreover, other population studies should be performed to replicate our findings.

**Acknowledgements**

We would like to express our gratitude to all patients who accepted to participate to this study. Authors are also grateful to Valiasr Hospital staff for their assistance.

**Conflict of interest**

The authors declared no conflict of interests.

**References**

Lack of Association of CYP2E1 and CYP1A1 Polymorphisms

29. Yang B, O'Reilly D A, Demaine A G, et al. Study of polymorphisms in the cyp2e1 gene in...